Dianthus Therapeutics (STU:87E) Float Percentage Of Total Shares Outstanding: 86.86% (As of Jul. 05, 2026)


STU:87E Dianthus Therapeutics Inc STU:87E
22 GF Score
Price €82.00
GF Value €2.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Float Percentage Of Total Shares Outstanding?

Dianthus Therapeutics STU:87E 22 Float Percentage Of Total Shares Outstanding is 86.86% as of Jul. 05, 2026. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Dianthus Therapeutics's float shares is 47.49 Mil. Dianthus Therapeutics's total shares outstanding is 54.67 Mil. Dianthus Therapeutics's float percentage of total shares outstanding is 86.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Dianthus Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Dianthus Therapeutics's Institutional Ownership is 57.40%.

STU:87E
22GF Score
Dianthus Therapeutics Inc STU:87E
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Dianthus Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=47.49/54.67
=86.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 86.86% mean?
Dianthus Therapeutics (STU:87E) has a Float Percentage Of Total Shares Outstanding of 86.86% as of Jul. 05, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Dianthus Therapeutics and its competitors.
Is Dianthus Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Dianthus Therapeutics' current Float Percentage Of Total Shares Outstanding is 86.86%. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Float Percentage Of Total Shares Outstanding compare to CAI and TNGX?
Dianthus Therapeutics' Float Percentage Of Total Shares Outstanding of 86.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Float Percentage Of Total Shares Outstanding is 86.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 86.86%. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current Float Percentage Of Total Shares Outstanding is 86.86% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:87E:

  • Float Percentage Of Total Shares Outstanding: 86.86%
  • GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges DNTH:USA
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for STU:87E

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.00
Price
€2.53
GF Value